AI assistant
Beta Bionics, Inc. — Director's Dealing 2026
Mar 3, 2026
32351_dirs_2026-03-03_8009c833-094c-44f4-bfb8-7c7c2e51c46b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2026-02-27
Reporting Person: Mensinger Mike (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-27 | Common Stock | A | 109105 | — | Acquired | 189857 | Direct |
| 2026-03-02 | Common Stock | S | 1064 | $12.3616 | Disposed | 188793 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-27 | Employee Stock Option (right to buy) | $12.63 | A | 58749 | Acquired | 2036-02-26 | Common Stock (58749) | Direct |
Footnotes
F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
F2: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F3: The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.